



BRITISH

MEDICAL JOURNAL



British Medical Journal Volume-2, No 4
10.5281/zenodo.6958172

British Medical Journal
Volume 2, No 1., 2022

Internet address: <http://ejournals.id/index.php/bmj>

E-mail: info@ejournals.id

Published by British Medical Journal

Issued Bimonthly

3 knoll drive. London. N14 5LU United Kingdom

+44 7542 987055

Chief Editor

Dr. Fiona Egea

Requirements for the authors.

The manuscript authors must provide reliable results of the work done, as well as an objective judgment on the significance of the study. The data underlying the work should be presented accurately, without errors. The work should contain enough details and bibliographic references for possible reproduction. False or knowingly erroneous statements are perceived as unethical behavior and unacceptable.

Authors should make sure that the original work is submitted and, if other authors' works or claims are used, provide appropriate bibliographic references or citations. Plagiarism can exist in many forms - from representing someone else's work as copyright to copying or paraphrasing significant parts of another's work without attribution, as well as claiming one's rights to the results of another's research. Plagiarism in all forms constitutes unethical acts and is unacceptable. Responsibility for plagiarism is entirely on the shoulders of the authors.

Significant errors in published works. If the author detects significant errors or inaccuracies in the publication, the author must inform the editor of the journal or the publisher about this and interact with them in order to remove the publication as soon as possible or correct errors. If the editor or publisher has received information from a third party that the publication contains significant errors, the author must withdraw the work or correct the errors as soon as possible.

OPEN ACCESS

Copyright © 2022 by British Medical Journal

British Medical Journal Volume-2, No 4

ELSEVIER



SSRN
Tomorrow's Research Today

Universal
Impact Factor



THE LEVEL OF ADIPOKINES (ADIPONECTIN AND LEPTIN) IN PATIENTS WITH OSTEOARTHRITIS

Ramazanova Nigora Asrarovna

Postgraduate student of the department Propedeutics of Internal Diseases No. 1
Tashkent Medical Academy Tashkent, Uzbekistan asrorovna1987@gmail.com

Abstract: The role of adipokines (adiponectin and leptin) is still controversial in the pathogenesis of osteoarthritis. This study investigated whether adipokines are involved in inflammation and joint destruction in OA. Also, this study explored the role of adipokines in the pathogenesis of OA with the background of metabolic syndrome.

Keywords: osteoarthritis, adipokine, adiponectin, leptin, metabolic syndrome.

Osteoarthritis (OA) is one of the fundamental social and medical problems. The importance of disease is that the prevalence of the disease is increased due to improving life expectancy and the incidence of obesity [1]. The World Health Organization (WHO) experts have recognized obesity as a new chronic "epidemic" of our time [2]. Adipose tissue is an active endocrine organ which synthesizes adipokines. Obesity is one of the main risk factors for the occurrence and progress of OA [3]. Several studies conducted in experiments and in patients with metabolic syndrome revealed that adipose tissue is an active endocrine organ, which can deposit pro-inflammatory factors - interleukin-1, tumor necrosis factor, adipokines (leptin, adiponectin, etc.), involved in the metabolism of chondrocytes, lipids, hemostasis and bone metabolism [5].

Adipokines have anti-inflammatory, antiatherogenic, and antidiabetic properties [5;8]. The adipokines levels remain poorly understood in degenerative-dystrophic diseases of the joints.

Adiponectin (AN) and leptin (LP) are two adipokines that play an important role in the relationship between obesity and associated metabolic disorders [6].

AN is a protein consisting of 244 amino acids and has a collagen-like region. This adipocytokine circulates in the blood plasma in various isoforms: low molecular weight trimer, medium molecular weight hexamer and high molecular weight oligomer, among which a biologically active form of the hormone is a high molecular weight oligomer [22].

AN is a hormone that is synthesized and secreted by adipose tissue, mainly adipocytes of the visceral region and is found in sufficient quantities in the blood - about 0.01% of the total protein plasma with a total concentration of about 5-10 µg/ml. AN secretion is stimulated by insulin [23]. Current data showed that adiponectin is synthesized by adipocytes of adipose tissue and other cells, including osteoblasts, liver parenchyma cells, myocytes, epithelial cells and placental tissue [8].

AN occurs its effects by receptors, which are found mainly in skeletal muscle (AdipoR1), as well as in the liver (AdipoR2). AN has a wide range of activity in diseases with an inflammatory component, such as cardiovascular disease, type 2 diabetes, metabolic syndrome, and OA [24]. The study by E. Distel et al. [25]



increased adiponectin production in knee OA. At the same time, another study found an inverse correlation between the level of adiponectin in plasma and synovial fluid and the severity of diseases according to radiological manifestations [25]. The level of adiponectin is significantly decreased in cardiovascular diseases, diabetes mellitus, and some types of malignant neoplasms [5]. The level of adiponectin in degenerative-dystrophic diseases of the joints remains poorly understood. There is literature evidence that an excessive amount of adipose tissue contributes to cartilage degradation, the development of inflammation in the joints, and the progression of OA [5, 6]. Disturbances in the general metabolism of adipose tissue hormones, primarily adiponectin, can lead to peroxide modification of lipoproteins, decreasing lipoprotein oxidation (LDL). The latter have increased immunogenicity, as a result of which antibodies (anti-LDL) begin to form against it. It is known that anti-LDL can cause complications in the pathogenesis of many diseases, such as encephalitis, vasculitis, and collagenases [3]. Indirect data indicate a possible effect of anti-LDL on the pathogenesis of OA. Some studies confirm the effect of LDL and anti-LDL on chondrocyte apoptosis and, as a result, cases of the development of certain joint diseases [7]. Thus, it can be suspected that lipid disturbance may play a role in the pathogenesis of osteoarthritis.

LP is one of the main adipokines involved in metabolic processes in OA. It is the protein product of a gene that was identified in 1994. LP is mainly produced by white adipose tissue cells and its circulation is directly related to the body's fat amount. LP is considered the essential regulator of body mass, decreases appetite and stimulates energy consumption via hypothalamic receptors. Basically LP production is regulated by meals, hormones, and inflammatory mediators such as TNF- α , IL-1, and IL-6. Inflammatory processes increase LP synthesis, while hunger and limited consumption of animal fats decrease LP concentration. The production of leptin is regulated by hormones, inflammatory mediators (such as TNF α , IL1, IL6) and food intake [15,16]. Increased leptin production increases alkaline phosphatase, osteocalcin, type I collagen and transforming growth factor beta-1, showing increased sensitivity to osteoblast dysregulation [17]. In patients with OA, leptin is found in large amounts in the synovial fluid and in the synovial membrane of the knee joints [18]. A 10-year study at the University of Michigan found an association between leptin levels and radiographic manifestations of OA in women. The authors found that an increase in the level of leptin by 5 ng/ml in the blood serum progresses radiological signs of OA by 38% and increases the risk of OA of the knee by 31% [26].

Materials and methods. Clinical studies of patients with OA were conducted in the departments of rheumatology and the RRC SKAL of the multidisciplinary clinic of the Tashkent Medical Academy for the period 2020-2021. Participation in the research was voluntary, and the principles of medical rationality were respected. The diagnosis of OA was confirmed based on classification representations of the American College of Rheumatology ACR (1991).

We conducted studies on the level of AN and LP in patients with OA. Participants were divided into two groups. The first group consists of 20 patients